Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines by Ana I. Manzano et al.
ORIGINAL ARTICLE
Structural studies of novel glycoconjugates from polymerized
allergens (allergoids) and mannans as allergy vaccines
Ana I. Manzano1 & F. Javier Cañada1 & Bárbara Cases2 & Sofia Sirvent3 & Irene Soria2 &
Oscar Palomares3 & Enrique Fernández-Caldas2 & Miguel Casanovas2 &
Jesús Jiménez-Barbero1 & José L. Subiza2
Received: 19 October 2015 /Revised: 15 November 2015 /Accepted: 18 November 2015 /Published online: 25 November 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Immunotherapy for treating IgE-mediated allergies
requires high doses of the corresponding allergen. This may
result in undesired side effects and, to avoid them, hypoaller-
genic allergens (allergoids) polymerized with glutaraldehyde
are commonly used. Targeting allergoids to dendritic cells to
enhance cell uptake may result in a more effective immuno-
therapy. Allergoids coupled to yeast mannan, as source of
polymannoses, would be suitable for this purpose, since
mannose-binding receptors are expressed on these cells.
Conventional conjugation procedures of mannan to proteins
use oxidizedmannan to release reactive aldehydes able to bind
to free amino groups in the protein; yet, allergoids lack these
latter because their previous treatment with glutaraldehyde.
The aim of this study was to obtain allergoids conjugated to
mannan by an alternative approach based on just glutaralde-
hyde treatment, taking advantage of the mannoprotein bound
to the polymannose backbone. Allergoid-mannan
glycoconjugates were produced in a single step by treating
with glutaraldehyde a defined mixture of allergens derived
from Phleum pratense grass pollen and native mannan (non-
oxidized) from Saccharomyces cerevisae. Analytical and
structural studies, including 2D-DOSY and 1H-13C HSQC
nuclear magnetic resonance spectra, demonstrated the feasi-
bility of such an approach. The glycoconjugates obtained
were polymers of high molecular weight showing a higher
stability than the native allergen or the conventional allergoid
without mannan. The allergoid-mannan glycoconjugates were
hypoallergenic as detected by the IgE reactivity with sera from
grass allergic patients, even with lower reactivity than conven-
tional allergoid without mannan. Thus, stable hypoallergenic
allergoids conjugated to mannan suitable for using in immu-
notherapy can be achieved using glutaraldehyde. In contrast to
mannan oxidation, the glutaraldehyde approach allows to pre-
serve mannoses with their native geometry, which may be
functionally important for its receptor-mediated recognition.
Keywords Mannan . Allergen . Allergoid . Glutaraldehyde .
Conjugation . Vaccine
Introduction
The immunotherapy of IgE-mediated allergic diseases is
based on the administration of increasing amounts of allergens
to desensitize allergic patients (allergen vaccines). For immu-
notherapy to be effective, high doses of allergens have to be
administered [1]. This raises major safety concerns due to the
sensitivity of the patients to the allergens that the vaccine
contains [1].
Immunotherapy with modified allergens to render them
hypoallergenic (allergoids) is increasingly being used, since
the safety profile of allergoids allows to a faster and simpler
dosing than with native (non-modified) allergens [2, 3].
Glutaraldehyde is the most widely used agent for allergoid
formation [4, 5]. By means of its two reactive aldehyde
groups, it cross-links the allergen proteins through the ε-
amino groups of lysine residues. This reaction results in aller-
gen polymerization, with the concomitant loss of accessibility
of IgE antibodies to the allergen epitopes, i.e., antibody bind-
ing sites, [4].
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The goal of allergy vaccines is to induce a therapeutic im-
mune response against the corresponding allergens. The main
initiators of such a response are dendritic cells (DCs), which
are continuously sampling antigens from the microenviron-
ment by receptor-mediated endocytosis, micropinocytosis
and phagocytosis [6]. C-type lectin receptors (CLRs) are piv-
otal for recognizing glycans, in a calcium-dependent manner
[7]. Key examples are mannose receptor (MR), Dectin-2 and
DC-SIGN, which preferentially recognize mannose residues
[8]. Therefore, antigen conjugation with mannan, as a source
of polymannoses, has been proposed to increase the antigen
uptake by DCs [9], including allergens [10]. While this con-
cept is of paramount interest for vaccine development, the
notion is even more evident when considering hypoallergenic
polymerized allergens, since it has been claimed that these
polymers are not efficiently captured by DCs [11].
Conventional methodologies for coupling mannan to pro-
teins require, as a first step, its prior oxidation (oxidized man-
nan) to release reactive aldehyde groups (−CHO) able to bind
to the protein amino groups [12]. This approach is however
not suitable for conjugating mannan to allergoids, because the
dramatic reduction of free amino groups once the protein has
reacted with glutaraldehyde [13].
Here we show a novel approach to obtain allergoid-
mannan glycoconjugates. Our concept is based on using just
a glutaraldehyde treatment, taking advantage of the
mannoprotein bound to the polymannose backbone of man-
nan. Analytical and structural studies show the feasibility of
such an approach, which results in a high molecular weight
and stable structure with a reduced IgE binding reactivity suit-
able to be used for allergen immunotherapy.
Material and methods
Allergens
Defatted grass pollen grains fromPhleum pratense (Iberpolen,
Jaén, Spain) were extracted overnight with phosphate buffered
saline, pH 7.2 (PBS) and submitted to tangential flow ultrafil-
tration (cut off pore size, 100 kDa). The enriched allergen
fraction obtained in the filtrate was dialyzed with distilled
water and lyophilized in small aliquots until used. Total pro-
tein content was measured by the Bradford assay using serum
albumin as standard (Bio-Rad Laboratories, Madrid, Spain).
Mannan from S. cerevisae
Mannan was obtained as described [14, 15] with slight mod-
ifications. Briefly, mannan was extracted from yeast
(Saccharomyces cerevisae; Lesaffre Ibérica, Madrid, Spain)
in hot citrate buffer (0.02 M; pH 7.0) during 90 min. The
extract was precipitated with ethanol and dialyzed against
distilled water. Mannan was precipitated in the presence of
cetavlon (Sigma-Aldrich, Madrid, Spain) (50 % v/v) after sev-
eral hours in a shaker by adding 2 % borate sodium (pH 8.8).
The precipitate was collected by centrifugation and washed
twice with 2 % acetic acid in ethanol plus a final wash with
100 % ethanol. Once re-dissolved and dialyzed in distilled
water, it was applied to a DEAE-Sephadex A-50 column
equilibrated with 0.02 M Tris-HCl buffer (pH 7.5). A linear
gradient from 0 to 0.5 M NaCl was used. Mannan-containing
fractions (M) were pooled, dialyzed extensively against dis-
tilled water and lyophilized in aliquots until used.
Allergen-mannan conjugation
Allergens from grass pollen Phleum pratense were polymer-
ized and conjugated with mannan in a single step as follows.
Glutaraldehyde (25 %, Sigma) was added to a solution (final
concentration 25 mM) containing a mixture of the allergen
and mannan in PBS. This mixture was made at different
allergen:mannan ratios (1:4; 1:1; 1:0.5; 1:0.3; 1:0.15), using
a fix protein amount and different amounts of freeze-dried
mannan. Reaction was performed during 6 h at 4 °C in con-
tinuous stirring and stopped with glycine (1.25 M), followed
by tangential flow filtration with distilled water (membrane
cut off, 100 kDa) to remove free allergen and mannan mole-
cules, virtually all of them below that size. Allergen-mannan
(AM) conjugates were recovered in the concentrated retentate
(>100 kDa fraction) that was further lyophilized until use.
Total carbohydrates and protein content of reconstituted sam-
ples were measured by the anthrone [16] and Bradford [17]
assays, respectively.
For control purposes, one part of the same allergen extract
remained untreated (native allergen, N) or subjected to the
above protocol but without mannan to obtain a conventional
mannan-free polymerized allergen (POL).
Gel electrophoresis (SDS-PAGE) and immunoblotting
Every allergen sample (N, POL and AM) was submitted to
protein separation in 12.5 % polyacrylamide gels under
denaturalizing conditions with sodium dodecyl sulfate and
Coomassie blue staining. Immunoblots were performed trans-
ferring the proteins separated by electrophoresis to cellulose
nitrate membranes (Bio Rad, Germany). Themembranes were
blocked with 5 % bovine serum albumin in PBS-0.1 % Tween
20 and incubated with a pooled serum from grass allergic
patients. Afterwards, they were incubated with an anti-
human IgE monoclonal antibody conjugated with peroxidase
(Southern Biotech, USA) at a 1/2000 dilution. ECL chemilu-
minescence system was used for reaction development (GE-
Healthcare, USA).
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Amino acid analyses
Samples adjusted at 1 mg/mL in protein were hydrolyzed with
HCl 6 N, during 24 h under vacuum at 110 °C. Amino acid
content was assessed by a quantitative amino acid analyzer
(Biochrom 30; Biochrom Ltd., Cambridge, UK). The process
requires the separation of the amino acids by cation exchange
chromatography and derivatization with ninhydrin [18].
Monosaccharide analyses
Neutral sugars were analyzed by gas chromatography in the
form of their alditol acetates [19]. The samples (1 mg) contain-
ing polysaccharides were first hydrolyzed with 3 M tri-
fluoroacetic acid (121 °C, 1 h). The released monosaccharides
were then converted into their corresponding alditol acetates by
reduction with NaBH4 (Sigma) and subsequent acetylation.
Identification and quantification were performed by gas-liquid
chromatography on a 6890A instrument (Agilent Technologies,
Santa Clara, California, USA) equipped with a flame-ionization
detector, using a HP5 fused silica column with He as the carrier
gas. Identification was performed on the basis of the coinci-
dence of the retention time of the sample components with
those previously measured for known monosaccharide refer-
ence standards analyzed under identical conditions and using
inositol as internal standard.
Nuclear magnetic resonance (NMR) studies
NMR spectra were obtained for samples (4 mg/mL in D2O) at
298 K. Standard 1H NMR and 2D-NMR experiments
(TOCSY, HSQC, DOSY) were employed using Bruker
Avance 500, 600 and 700 MHz spectrometers (Bruker Ltd.,
Germany). For heteronuclear 2D-NMR (HSQC), experiments
were acquired with 2 K points in a spectral width of 9 ppm in
the 1H dimension and 110 ppm, center at 55 ppm, in the 13C
dimension and 256 increments. A relaxation delay of 1 s, and a
J-evolution delay corresponding to a J value of 155 Hz were
used.13C decoupling was achieved by the WALTZ scheme.
Standard conditions were employed for the homonuclear 2D-
NMR (TOCSY) experiments, with a 50 ms mixing time. The
two dimension diffusion ordered spectroscopy (2D-DOSY) ex-
periments were carried out by recording 64–128 scans for each
gradient step, a linear gradient of 16 steps between 2 % and
95%, a diffusion time (big delta) between 0.2 and 0.4 s, and the
length of the diffusion encoding gradient pulses (little delta)
between 2-4 ms. Dextran markers of different MW were used
to perform a calibration curve to obtain the diffusion coeffi-
cients (m2 s−1) as a function of the MW. [20]. All spectra were
processed with the protocols implemented in Topspin software
(Bruker Ltd). These samples (4 mg/mL in D2O) were stored in
closed vials at 4 °C during four months to assess the stability of
allergen-mannan glycoconjugates (AM) in comparison to na-
tive (N) or just polymerized (POL) preparations.
Specific IgE immunodetection assay
IgE reactivity to the different allergen samples (N, POL and
AM) was tested by an immunodetection assay as previously
described [21]. Briefly, a total protein amount of 30 μg of the
different allergen preparations were placed onto nitrocellulose
membranes using a Whatmann Univac vacuum manifold sys-
tem (GE Healthcare, Canton MA, USA) for allergen binding.
The membranes were neutralized with a blocking solution
(PBS-0.1 % Tween 20; 3 % defatted milk protein preparation)
and incubated (16 h at 4 °C) with individual sera diluted 1/10
from grass pollen allergic patients or with a pool of sera at the
same dilution. Afterwards, the membranes were washed with
PBS-0.1 % Tween 20 and incubated 1 h at room temperature
with anti-human IgE monoclonal antibody diluted 1/5000
followed by a 1 h incubation with a rabbit anti-mouse mono-
clonal antibody conjugated with peroxidase diluted 1/2000
(Dako, Barcelona, Spain). After washing the membranes with
PBS-0.1 % Tween 20, the ECL chemiluminescence system
was used for reaction development (GE-Healthcare, Canton
MA, USA). Volummograms of the reactive spots were ana-
lyzed by scanning densitometry using FUJI FILM
MultiGauge v3.0 software.
Results
Allergen conjugation with mannan from S. cerevisae
Conjugation of allergens to the purified yeast mannan was per-
formed with glutaraldehyde in a single step as decribed in
Material and Methods. The purified mannan was very similar
to that commercially available as detected by NMR (Fig. 1a),
contained almost only mannose (97 %) (Fig. 1b), and contained
lysine (883 ng/mg mannan) within other aminoacids (Fig. 1c).
For conjugation, different allergen:mannan ratios were used (see
Material andMethods). Bymeasuring total carbohydrates, it was
found that the AM fraction contained up to 60 % carbohydrates.
The lowest amount of mannan to achieve the highest carbohy-
drate content was obtained at 1:0.5 (allergen:mannan) ratio. As
higher amounts of mannan (1:1 and 1:4 ratios) did not increase
that percentage, the 1:0.5 ratio was established for further studies.
Analytical studies of the AM fraction
Figure 2 shows the percentage of neutral monosaccharides in
the AM fraction in comparison with the same fraction (POL)
obtained by treating allergens with glutaraldehyde without
mannan. As could be expected a strong increase (over 20-
fold) of mannoses was seen in the AM fraction, rising to up
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40 % of relative content, whereas the other main sugars (arab-
inose and galactose) decreased. Some glucose was also ob-
served probably due to variability of the crude extracts where
its presence has been described [22].
Figure 3 shows the protein profile of AM fraction by gel
electrophoresis as detected by protein staining (Coomassie
blue) and immunoblotting. Similar to the POL fraction, no
bands were detectable in any assay within the gel, in contrast
to the lanes loaded with the native allergen (N), in which
major allergens from Phleum pratense (red box) were readily
seen. The results indicated that molecules in the AM fraction
were extensively polymerized as did occur when allergens
were treated with glutaraldehyde in the absence of mannan.
Structural studies of the AM fraction
The structure of AM fraction was addressed by NMR as de-
scribed in Material and Methods. As shown in Fig. 4a, the
saccharide signals in the NMR spectra were increased in frac-
tion AM (different conjugation ratios) as compared with the
control fraction (POL). 2D-DOSY was performed to detect
the presence of heterogeneity, as well as to estimate the aver-
age size of the different components in the allergen-mannan
conjugates (Fig. 4b). As shown, the different AM fractions
showed larger sizes than the POL fraction without mannan,
pointing to supramolecular entities formed by association be-
tween the protein allergens and mannan.
Figure 5a shows that NMR signals for the different spectral
regions showed a constant and significant broadening in the
glutaraldehyde-treated samples (AM and POL fractions) as
compared with the untreated allergen (N), suggesting the ex-
istence of molecular heterogeneity and/or fast transverse re-
laxation, which is associatedwith largemolecular size entities.
The analysis of the translational diffusion 2D-DOSY spec-
trum further demonstrated the increase of the average molec-
ular size in the glutaraldehyde-treated samples, remarkably in
the AM fraction. In this particular case, even larger molecular
entities could be inferred from the 2D-DOSY spectra
(Fig. 5b). To assess more accurately these size differences, a
semi-quantitative molecular weight estimation was carried out
in DOSY experiments using the self-diffusion coefficient D
(m2 s−1) and uncharged saccharides (dextran) as standards [20,
23]. The AM fraction showed the highest molecular weight,
approximately 5-fold above the POL fraction and 25-fold
above the average of the untreated allergen (data not shown).
Figure 6 shows the analysis of the 1H-13C HSQC spectra of
the allergen-mannan conjugates. As shown, new NMR signals
in the carbohydrate region of AM fraction were seen when
comparing with the POL fraction in absence of mannan. Some
of these are mannan specific signals that have been identified in
this spectrum [24], and also arabino-galactan signals described
in Phleum pratense extracts [25]. This fact unequivocally con-
firmed the existence of allergen-mannan complexes and there-
fore the presence of true allergen-mannan glyconjugates in a
stable supramolecular structure.
Stability of allergen-mannan glycoconjugates
To assess the stability of the allergen-mannan glycoconjugates
contained in AM fraction, its structure was analyzed by NMR
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Fig. 1 aRepresentation of the different 1 HNMR spectra for the purified
mannan and commercial mannan (Sigma M3640). Both the carbohydrate
(5–3 ppm) and the aliphatic protein regions (3-0 ppm) are displayed; b
Monosaccharide analysis in the purified mannan (%); c) Amino acids
analysis representation in the purified mannan (ng/mg), the black
column showing lysine. Results for b and c are expressed as the mean
of duplicates ± SD.
just after the conjugation process (t0) and 4 months later (t1).
Samples in solution with heavy water (D2O) were stored at
4 °C. These included also samples of untreated native allergen
(N) and glutaraldehyde-treated allergen without mannan
(POL) for comparison purposes at the same protein
concentration and storage conditions. As shown in Fig. 7,
the difference of NMR signals in the AM fraction conjugated
with mannan decreased by only 4 % at t1. By contrast, at that
time, a remarkable signal loss was scored for the native aller-
gen (N) (above 40 %) and 14 % for the POL fraction (poly-
merized allergens without mannan). These results indicated
that the structure of allergen-mannan glycoconjugates obtain-
ed in fraction AM is remarkably stable as compared with the
native allergen, but also more stable than the polymers obtain-
























Arabinose Mannose Glucose Galactose
Fig. 2 The percentage of
monosaccharides in fraction AM
(allergen-treated with
glutaraldehyde in the presence of
mannan) and fraction POL
(allergen-treated with
glutaraldehyde in the absence of
mannan). POL and AM were
fractions recovered in the
retentate after tangential
ultrafiltration (100 kDa pore size
membranes). Results are
expressed as the mean of
duplicates ± SD
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Carbohydrate region Aliphatic region
Fig. 4 NMR analysis for the different Phleum pratense allergen
preparations. a Superimposition of the different 1H NMR spectra
recorded. Both the carbohydrate (5–3 ppm) and the aliphatic protein
regions (3-0 ppm) are displayed; b Superimposition of the different
DOSY experiments recorded. Carbohydrate (5–3 ppm) region are
displayed. AM (allergen-treated with glutaraldehyde in the presence of
mannan); POL (allergen-treated with glutaraldehyde in the absence of
mannan). AM and POL were fractions recovered in the retentate after
tangential ultrafiltration (100 kDa pore size membranes).
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Fig. 3 Protein (protein staining: Coomassie blue) and allergen
(immunoblotting: IgE) patterns of Phleum pratense allergen
preparations as detected in SDS-PAGE and Western blot. Lane N:
native allergen extract; Lane POL: glutaraldehyde-treated allergen
without mannan; Lane AM: glutaraldehyde-treated allergen with
mannan. AM and POL were fractions recovered in the retentate after
tangential ultrafiltration (100 kDa pore size membranes)
IgE reactivity with allergen-mannan glycoconjugates
Finally, we were prompted to test if the allergen-mannan
glycoconjugates were so hypoallergenic as the conventional
allergoids. This was assessed by a quantitative dot blot immu-
noassay, testing sera from grass pollen allergic patients as
described in Material and Methods with the different allergen
preparations. As shown in Fig. 8, the IgE reactivity to the
allergen-mannan glyconjugate (AM) was significantly less in-
tense than to the native allergen (N), and even less than to the
glutaraldehyde-treated allergens without mannan (POL),
though in a lower extent. These results indicated that
allergen-mannan conjugates were hypoallergenic, and there-
fore suitable to be used for immunotherapy.
Discussion
Coupling of allergens to mannan has been suggested as a way
to enhance the allergen uptake by DCs and therefore the
efficacy of immunotherapy with allergens [10]. This approach
could be even more interesting in the case of allergoids, since
it has been claimed that glutaraldehyde-modified allergens are
less immunogenic than native allergens (non-modified) due to
a lower uptake by DCs [11]. The purpose of this study was to
obtain glutaraldehyde-modified allergens conjugated to man-
nan, taking into account that the conventional conjugation
procedure using oxidized mannan was not feasible due to
the lack of free amino groups in the allergoids [13].
Here we show that stable allergoids conjugated with man-
nan can be produced by treating with glutaraldehyde a mixture
of allergen and non-oxidized mannan. These glycoconjugates
are likely formed through the reaction of the di-aldehyde with
the lysine free amino groups of proteins derived from both the
allergen and the mannoprotein, i.e., the protein tail linked to
the mannan carbohydrate backbone [26]; thus, bridging both
molecules by means of glutaryl-diimine bonds. The presence
of detectable lysine in our purified mannan preparation (al-
most 1 μg per mg of mannan) supports such a mechanism.
Of note, lysine was also present in all commercially available
D
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Fig. 5 NMR analysis for the different Phleum pratense allergen
preparat ions (N, POL, AM) and purif ied mannan (M). a
Superimposition of the different 1H NMR spectra recorded for the
different samples. Both the carbohydrate (5–3 ppm) and the aliphatic
protein regions (3-0 ppm) are displayed; b Superimposition of the
different 1H NMR spectra and DOSY experiments recorded for the dif-
ferent samples. Both the carbohydrate (5–3 ppm) and the aliphatic protein
region (3-0 ppm) are displayed. Monodimensional DOSY projections
represented in the BY^ axis. AM (allergen-treated with glutaraldehyde
in the presence of mannan); POL (allergen-treated with glutaraldehyde













Fig. 6 NMR analysis for the different Phleum pratense allergen
preparations: allergen-treated with glutaraldehyde in the presence of
mannan (AM); allergen-treated with glutaraldehyde in the absence of
mannan (POL) and purifiedmannan (M). Superimposition of the different
1H-13C HSQC spectra: AM (blue); POL (black) and M (yellow). Signals
from Arabino-galactan following assignment by Brecker et al. [25];
Signals from Mannans following assignment by Vinogradov et al. [24].
Assignment of the carbohydrate anomeric zone: α/βAra (α/β arabinose),
βGal (βGalactose), bcM (branched chain mannose), ucM (unsubstituted
chain mannose), ibM (2-substituted internal branched mannose), tbM
(terminal branched mannose)
98 Glycoconj J (2016) 33:93–101
fractions recovered in the retentate after tangential ultrafiltration (100 kDa
pore size membranes).
mannan from Saccharomyces cerevisae tested so far (data not
shown). The structural studies by NMR show a clear interac-
tion between the allergen and mannan after glutaraldehyde
treatment, resulting in high molecular weight complexes. In
fact, the broadening of the signals in the allergen-mannan
samples indicates a size increase of the complexes as also
noted by SDS-PAGE. This is corroborated in translational
diffusion DOSY NMR spectra. These complexes showed
the lowest diffusion coefficient, as compared with untreated
native allergen or glutaraldehyde-treated allergen without
mannan, indicating the presence of a molecular entity of larger
size. This also evidenced a stable interaction between the
allergoid and mannan, since both parts of the spectrum (the
carbohydrate and protein areas) show the same diffusion co-
efficient. Additionally, NMR studies based on HSQC
(heteronuclear correlation 13C-1H) experiments confirmed
such interaction, since the allergen-mannan conjugates had
the characteristic carbohydrate signals of mannan and also of
the intrinsic carbohydrates of the allergen. It should be noted
that, in HSQC experiments, every C-H pair of the molecular
entity displays a signal with well-defined position, depending
on its chemical environment. Thus, the complete set of signals
compose a molecular fingerprint, which can be ascribed to a
given component [27]. Interestingly, the allergen-mannan
glycoconjugates prepared with glutaraldehyde seem to be fair-
ly stable during at least several months, as deduced by their
subtractive spectrum by NMR. In fact, they were more stable
than the untreated native allergen or the glutaraldehyde-
treated allergen without mannan. The remarkable structural
stability of allergen-mannan glycoconjugates is clearly an ad-
vantage from the perspective of a vaccine development, be-
cause the possibility of a longer shelf life.
We have also shown that the allergen-mannan
glycoconjugates prepared with glutaraldehyde display a re-
duced allergenicity. The extent of reactivity of these
glycoconjugates with specific IgE was even lower than
that observed for the conventional allergoids, i.e., poly-
merized allergens without mannan. The higher molecu-
lar weight of allergen-mannan conjugates may explain
this fact, since it is considered that the reduced IgE
reactivity with the allergoids depends on the loss of
accessibility (steric hindrance) of the antibodies to the
allergen epitopes after polymerization [28].
It is important to note that the conjugation approach we
describe here preserves the carbohydrate structure of mannan
without denaturation, in contrast to the widely used oxidative
methods [29]. Oxidation breaks the mannopyranose rings
within the polymannose backbone producing remarkable
structural consequences [30–32], that may affect its biological
properties such as the interaction with antibodies and lectins
[33–35]. This is of utmost importance when considering the
interaction of mannoses with their corresponding lectin recep-
tors on DCs. In fact it has been already shown that the state of
oxidation of mannan may modify the behavior of these cells
upon activation [36]. Functional studies from ourselves point
to the same direction (Sirvent et al., submitted for publication)
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Fig. 7 Stability study as detected by NMR analysis for the different
Phleum pratense allergen preparations stored at 4 °C (N, POL, AM).
1H NMR spectra was recorded immediately after their preparations (t0)
and four months later (t1). The intensity differences of the key NMR
signals between t0 and t1 are highlighted as a percentage (upper part).
AM (allergen-treated with glutaraldehyde in the presence of mannan);
POL (allergen-treated with glutaraldehyde in the absence of mannan);
N (native allergen extract). AM and POL were fractions recovered in
the retentate after tangential ultrafiltration (100 kDa pore sizemembranes)
Fig. 8 IgE reactivity with the different Phleum pratense allergen
preparations (N, POL, AM) as measured by dot blot. a Quantification
of the IgE binding from sera of grass pollen allergic patients by scanning
(mean values ± SD); bDot blot results obtained for 5 individual sera and a
pooled serum from patients allergic to grass pollen. N (native allergen
extract); POL (allergen-treated with glutaraldehyde in the absence of
mannan); AM (allergen-treated with glutaraldehyde in the presence of
mannan). AM and POL were fractions recovered in the retentate after
tangential ultrafiltration (100 kDa pore size membranes).
supporting the suitability of the conjugation approach we de-
scribe here to produce neoglycoconjugates with mannan to be
used in the development of novel vaccines.
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